55 filings
Page 2 of 3
8-K
jtjy ww70
7 Nov 22
Inhibrx Reports Third Quarter 2022 Financial Results
4:05pm
8-K
ms0dz
26 Oct 22
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:10pm
8-K
c7t8 xwbo
4 Oct 22
Entry into a Material Definitive Agreement
8:02am
8-K
bmxkkbswwnv pmuilu
15 Aug 22
European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma
4:09pm
8-K
wnkw44xs6n37
10 Aug 22
Regulation FD Disclosure
4:06pm
8-K
yyh16sdr3gazxogghede
8 Aug 22
Inhibrx Reports Second Quarter 2022 Financial Results
4:19pm
8-K
o1kj2btmh84hlkroioi3
30 Jun 22
Regulation FD Disclosure
9:01am
8-K
blox9asez9kxhpb9sf7h
16 Jun 22
Entry into a Material Definitive Agreement
4:05pm
8-K
2slqua2ur5mng5s7sup1
25 May 22
Submission of Matters to a Vote of Security Holders
5:23pm
8-K
5j0amx0qe0h
16 May 22
Regulation FD Disclosure
9:03am
8-K
7xony5
9 May 22
Inhibrx Reports First Quarter 2022 Financial Results
4:10pm
8-K
8xwnz
25 Apr 22
Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101
9:04am
8-K
bop65o
5 Apr 22
Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting
4:32pm
8-K
hrb1hn949y
4 Apr 22
Regulation FD Disclosure
4:06pm
8-K
e1l40t
3 Mar 22
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
9:22am
8-K
9clvnza2tw z6
28 Feb 22
Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results
4:12pm
8-K
mzpoiq40o1ut9fa94
22 Feb 22
Inhibrx Announces Amended Loan Agreement with Oxford
9:11am
8-K
uqlipj r4h
25 Jan 22
Departure of Directors or Certain Officers
12:00am
8-K
jymm9
4 Jan 22
Regulation FD Disclosure
4:41pm
8-K
1lj 85d2msk
1 Dec 21
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma
4:07pm